iShares MSCI South Africa ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? iShares MSCI South Africa ETF trades at $62.57 (market cap $466.20M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 54.2× iShares MSCI South Africa ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while iShares MSCI South Africa ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Africa ETF for 70 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| EZA | RPRX | |
|---|---|---|
Market Cap | $466.20M | $25.27B |
Volume | 152,369 | 3,671,183 |
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $63.96 |
52-Week Low | $60.43 | $35.44 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
EZA trades at $62.29, down 2.15% today, with a bearish technical signal driven by moving averages. The ETF's portfolio faces headwinds from global reflation impacting its heavy exposure to South African gold, banking, and platinum group metals. Key oscillators like the 6-day and 12-day relative strength index indicate oversold conditions, suggesting potential for a near-term bounce, but the average directional index signals a strong downtrend.
The outlook is cautious due to macroeconomic pressures on constituent companies, with risks from higher capital costs and commodity price volatility. Investment opportunity hinges on a reversal in global yield curves and commodity markets, but current sentiment remains negative amid sell-side dominance and lack of positive fundamental catalysts.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →